Genprex, Inc. Common Stock (GNPX) Stock Price
GNPXStock
$2.11−99.60%52W
Market Cap$1.73M
P/E—
PEG Ratio—
Div yield—
Beta-0.94
GNPX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-101.98%
Price vs S&P 500 (4W)-38.04%
VGM Score4.47
GNPX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q1 2025 | -$451.00 | -$286.00 | +36.59%(+$165.00) | |
| Q3 2024 | -$3003.00 | -$1353.00 | +54.95%(+$1650.00) | |
| Q2 2024 | -$2530.00 | -$3300.00 | -30.43%(-$770.00) |
GNPX Analyst Recommendations
Jun 2025
Jul 2025
Aug 2025
Oct 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
GNPXGenprex, Inc. Common Stock | — | — | F | — | — | — | — | $2.11 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Genprex, Inc. Common Stock
Genprex Inc develops non-viral gene therapies for cancer and diabetes. The company's Oncoprex Delivery System uses lipid nanoparticles to deliver therapeutic genes, with its lead candidate Reqorsa under evaluation in three clinical trials for non-small cell and small cell lung cancer.